Author  
Place of duty  
Title   불응성 난소암 환자에서의 Paclitaxel / Ifosfamide 투여에 대한 제 1 상 임상연구 ( Phase 1 clinical Trial of Paclitaxel Plus Ifosfamide for the Patients with Refractory Ovarian Cancer )
Publicationinfo   2000 Jan; 032(05): 895-904.
Key_word   Ovary neoplasm, Chemotherapy, phase I, Paclitaxel, Ifosfamide, Dose Iimiting toxicity,Maximum tolerated dose
Full-Text  
Abstract   Purpose: Patients with advanced ovarian carcinoma and refractory to platinum based chemotherapy have a very poor prognosis and effective salvage regimens are needed. This study was conducted in order to determine the maximum tolerated dose (MTD) and dose limiting toxicity of combination with paclitaxel and ifosfamide. Materials & Methods: After premedication, patients received paclitaxel (110 225 mg/m) as a 24 hour IV infusion on day 1. Ifosfamide (1,000-1,500 mg/m) was given as a 12 hour IV infusion with standard dose of mesna on day 2-6. All patients received G-CSF (granulocyte colony stimulating factor) on day 6-15. Results: 12 patients with advanced ovarian cancer entered this trial. Toxicity included bone marrow suppression, neuromuscular toxicity, urothelial toxicity, gastrointestinal toxicity, which occurred in 84.6%, 65.3%, 30.7%, 88.4% of cycles. Conclusion: Neuromuscular toxicity was dose limiting toxicity. Maximum tolerated dose in combination with paclitaxel and ifosfamide was 175 mg/m2 of paclitaxel and 1,500 mg/m of ifosfamide.
저 자   서호석(Ho Suk Saw),이재관(Jae Kwan Lee)